Top 7 findings on 2017 global EMR market

Electronic medical records (EMRs) now span all over the globe, but some are doing better than others at traveling abroad. The recently released “Global EMR Market Share 2017” report, conducted by KLAS, evaluated new contracts to EMR systems around the world.

Analyzing data from 201 from 238 global hospitals, the report found low-cost InterSystems and higher-cost Epic lead EMRs in new contracts against their multiregional and regional competitors.

Additional findings included:

1.      MV, Agfa HealthCare and ChipSoft continue to hold ground against multiregional vendors.

2.      Low-cost Intersystems hold 33 percent of contracts in the UK, sharing the top spot with DXC Technology who also hold 33 percent of contracts.

3.      Cerner maintains a strong hold as the most-used EMR by public hospitals in the Middle East as well as expanding to private hospitals Qatar, UAE and Kuwait.

4.      Private Middle Eastern hospitals have a wider expanse of choices in EMRs with MIMSYS implemented in the UAE, Qatar, South Africa, and Lebanon.

5.      While MEDITECH still holds the majority of the estimated hospital market share in Canada, 2016 gave rise to Epic in the country with two additional organizations.

6.      InterSystems remains the leader in Asia with China and Thailand expanding use, followed by Allscripts in Singapore and Napier in the Philippines and Malaysia.

7.      Few decisions were made in Oceania in 2016, with one hospital adding a contract with Cerner in Queensland, Australia. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.